Treatment with tofacitinib 5 mg twice daily was evaluated in 13 children with chronic fibrodysplasia ossificans aged 2.2 to 19.6 years:
- it reduced the mean number of heterotopic ossification flare-ups from 10 in the 12 months preceding the start of treatment to 0 in the 24 months that followed.
- thirty-one per cent of patients showed an improvement in the mobility of their large joints.
- after two years, non-steroidal anti-inflammatory treatments were significantly reduced and corticosteroids were completely stopped.
- the treatment was well tolerated with no severe side effects.
